Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.83 |
| ▸ | RAB9A | P51151 | 1/20 | 0.83 |
| ▸ | FAAH | O00519 | 2/20 | 0.63 |
| ▸ | LHCGR | P22888 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.58 |
| ▸ | DRD2 | P14416 | 1/20 | 0.55 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.55 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.55 |
| ▸ | RELA | Q04206 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899171 | 0.93 | ALDH1A1 (0.73) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL5115600 | 0.93 | ALDH1A1 (0.97) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL8395644 | 0.93 | ALDH1A1 (0.90) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL2783373 | 0.92 | ALDH1A1 (0.71) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL30407307 | 0.92 | RAB9A (0.71) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL1532563 | 0.91 | ALDH1A1 (1.00) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL21618461 | 0.91 | ALDH1A1 (1.00) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL8393776 | 0.91 | ALDH1A1 (1.00) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| SCHEMBL7781314 | 0.90 | ALDH1A1 (0.69) | ALDH1A1RAB9AFAAHLHCGREPHX1 | |
| Bicarbonate SCHEMBL15226094 | 0.90 | ALDH1A1 (0.97) | ALDH1A1RAB9AFAAHLHCGREPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694874-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2026-01-08 | — | — | US | disclosed |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | Rubedo Life Sciences, Inc. (US) | 2025-12-02 | — | — | US | disclosed |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | RUBEDO LIFE SCIENCES INC (US) | 2025-10-16 | — | — | US | disclosed |
| EP-4004001-B1 | SUBSTITUTED PYRIMIDINEDIONE COMPOUNDS AND USES THEREOF | SUNSHINE LAKE PHARMA CO LTD (CN) | 2025-09-03 | — | — | EP | disclosed |
| EP-4539840-A1 | KINASE MODULATORS AND METHODS OF USE THEREOF | Neuron23, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| CN-119730846-A | Kinase modulators and methods of use thereof | 神经元23公司 | 2025-03-28 | — | — | CN | disclosed |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | Rubedo Life Sciences, Inc. | 2024-12-12 | — | — | US | disclosed |
| WO-2024249613-A2 | GPX4 INHIBITORS AND SENOLYTIC COMPOUNDS AND USES THEREOF | Rubedo Life Sciences, Inc. (US) | 2024-12-05 | — | — | WO | disclosed |
| CN-119019380-A | Benzimidazole-6-sulfonylurea compound and medical application thereof | 南京羚诺生物医药技术研究院有限公司 | 2024-11-26 | — | — | CN | disclosed |
| EP-1415987-A1 | NITROGENOUS AROMATIC RING COMPOUNDS | Eisai Co., Ltd. (JP) | 2004-05-06 | — | — | EP | disclosed |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2004-03-18 | — | — | US | disclosed |
| CN-1478078-A | Nitrogen-containing aromatic ring derivatives | ������������ʽ���� | 2004-02-25 | — | — | CN | disclosed |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-07-17 | — | — | US | disclosed |
| WO-2003018019-A2 | NEW USE OF CYCLIC COMPOUNDS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2003-03-06 | — | — | WO | disclosed |
| EP-1259499-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-11-27 | — | — | EP | disclosed |
| WO-2001060808-A1 | THIAZEPINYL HYDROXAMIC ACID DERIVATIVES AS MATRIX METALLOPROTEINASE INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2001-08-23 | — | — | WO | disclosed |
| US-5864043-A | CARDIOVASCULAR DISORDERS AND ANGIOTENSIN ANTAGONIST | KARL THOMAE GMBH (DE) | 1999-01-26 | — | — | US | disclosed |
| US-5541229-A | ANGIOITENSIN II ANTAGONIST AS HYPOTENSIVE AGENTS, ANTIISCHEMIC AGENTS AND CARDIOVASCULAR DISORDERS | DR. KARL THOMAE GMBH (DE) | 1996-07-30 | — | — | US | disclosed |
| US-4721523-A | Herbicidal agents containing photosynthesis-inhibiting herbicides in combination with carbamate derivatives | BAYER AKTIENGESELLSCHAFT (DE) | 1988-01-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260007689-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX4 | ALDH1A1 732/4885RAB9A 2614/4885FAAH 2013/4885 |
| US-20040053908-A1 | Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective | VEGFA, UACA, UTS2R | ALDH1A1 1164/4885RAB9A 3247/4885FAAH 1560/4885 |
| US-20250319109-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | ALDH1A1 729/4885RAB9A 3340/4885FAAH 2779/4885 |
| US-20030134849-A1 | Thiazepinyl hydroxamic acid derivatives as matrix metalloproteinase inhibitors | MMP9, MMP1, MMP3 | ALDH1A1 543/4885RAB9A 3292/4885FAAH 664/4885 |
| US-20240408124-A1 | GPX4 Inhibitors and Senolytic Compounds and Uses Thereof | GPX4, GPX1, PRDX3 | ALDH1A1 729/4885RAB9A 3340/4885FAAH 2779/4885 |
| US-12485132-B2 | GPX4 inhibitors and senolytic compounds and uses thereof | GPX4, GPX1, PRDX3 | ALDH1A1 729/4885RAB9A 3340/4885FAAH 2779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.